Xiromed, the New Jersey-based generic division of Insud Pharmaceuticals — a global pharmaceutical group headquartered in Madrid, Spain — is offering progesterone injection 500 mg/10 ml (50 mg/ml) in a multiple-dose vial.
The medication is the generic of progesterone injection, which is used to restore normal menstrual periods (amenorrhea) or treat abnormal bleeding due to low hormone levels.
Progesterone injection 50 mg/ml and its generics had a market value of $20.4 million for the 12-month period ending February 2022, according to IQVIA.
“This is Xiromed’s second U.S. product launch from our dedicated hormonal injectable facility, Laboratorios Farmalan, located in Leon, Spain,” said Donna Genova, senior vice president of sales and commercial operations. “Xiromed continues to execute on our strategy to bring a robust portfolio of hormonal injectable products to the U.S. market.”
Kellogg’s Frosted Flakes celebrates ‘Obi-Wan Kenobi’ premiere with limited-edition cereal
Just weeks before the premiere of the “Obi-Wan Kenobi” series on Disney+, Kellogg’s Frosted Flakes joined forces with Lucasfilm on the launch of a new limited-edition cereal.
The new Kellogg’s Frosted Flakes Obi-Wan Kenobi cereal reflects the series’ dark and light side with a combination of the brand’s chocolate and classic flavors.
“For decades, ‘Star Wars’ has united fans across generations for movie nights, and we look forward to doing the same at the breakfast table with the release of our new Kellogg’s Frosted Flakes Obi-Wan Kenobi cereal,” said Sadie Garcia, director of brand marketing at Kellogg All Family Cereal.
In addition, the packaging even features Tony the Tiger sporting his best Obi-Wan Kenobi and Darth Vader attire in honor of the upcoming series, which premieres on May 27 on the streaming platform.
Kellogg’s Frosted Flakes Obi-Wan Kenobi cereal will be available at retailers nationwide beginning in July at the suggested retail price of $4.29 for a 10.7-oz. box and $5.29 for a 17.1-oz. box.
Supernus obtains FDA nod for new indication of Qelbree
Supernus Pharmaceuticals, a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, has received the Food and Drug Administration’s blessing for an expanded indication of Qelbree (viloxazine extended-release capsules) for the treatment of attention deficit hyperactivity disorder in adult patients aged 18 years old and older.
Qelbree is now approved for the treatment of ADHD in children, starting at age 6 years old, adolescents and adults.
“Until today, nonstimulant ADHD options for adults have been very limited,” said Greg Mattingly, founding partner of St. Charles Psychiatric Associates in St. Louis. “This approval is positive news and offers a new novel option for the millions of American adults who are trying to find the right treatment to manage their ADHD symptoms.”
Approximately 16 million children, adolescents and adults have ADHD in the United States. While many children with ADHD outgrow it, up to 90% of those diagnosed with ADHD in childhood continue to have ADHD as adults, the company noted.
“As a leader in the field of CNS, we are fully committed to better understanding how to treat complex diseases such as ADHD,” said Jack Khattar, president and CEO of Supernus Pharmaceuticals.
“Today’s approval marks a major advancement in the treatment of ADHD and is an important milestone just one year after the approval of Qelbree to treat pediatric patients,” Khattar said. We are proud to bring a new novel nonstimulant option for adults into the market after two decades.”
Sally Hansen throws it back to the ’90s with ‘Friends’ collection
Sally Hansen is pivoting back to the ’90s with a collection of nail polishes inspired by the classic TV series “Friends.”
The beauty brand is rolling out 10 new shades of its Miracle Gel line that were influenced by iconic moments on the show.
Featuring a chip-resistant and long-lasting formula that can keep a fresh manicure for up to eight days, the “Friends” collection is designed to help consumers channel their inner Rachel, Monica, Phoebe, Ross, Joey and Chandler, the company said.
The collection features the following hues: Oh. My. Coffee, Central Pink, A Moo Point, Lavendoor, Yellow Taxi, Stick To The Routine, The One With The Teal, How You Bluein’?, Pivot and He’s Her Lobster.
Retailing for $9.99 each, Sally Hansen’s “Friends” collection is available at mass market, drug store, food and e-commerce retailers nationwide.
The Consumer Healthcare Products Association is welcoming Logan Tucker as director of communications and media relations.
In this role, Tucker will serve as the primary contact for directing CHPA’s media strategies and tactics, and coordinate with other communications department staff to manage news, events and issues in the consumer healthcare industry. She will report to Anita Brikman, the organization’s senior vice president of communications and public affairs.
“CHPA is thrilled to welcome Logan to our staff,” said Brikman. “With more than a decade of combined legislative, communications and consulting experience, Logan’s professional background will certainly add value to our association’s communications department while enhancing our ability to amplify the impact of CHPA’s initiatives.”
Tucker joins CHPA from Deloitte, where she was a senior consultant in the firm’s government and public services sector, serving clients at both the federal and state levels. Prior to Deloitte, Tucker spent nearly 10 years on Capitol Hill, where she served in numerous communications roles, including as deputy chief of staff and communications director for Congressman Mark Amodei of Nevada.
“I’m honored to join the CHPA team, and additionally grateful for the opportunity to highlight the important work our member companies do each day to ensure American consumers are able to pursue happier and healthier lives through responsible self-care,” Tucker said.
She also previously served as communications director for Congressman Stephen Fincher of Tennessee and as a press assistant for Wyoming Senator John Barrasso. Tucker is an Austin, Texas native who has a bachelor’s degree in public relations from Texas Tech University.
Advanz Pharma, a pharmaceutical company with a strategic focus on specialty pharmaceuticals, specialty and hospital generics in Europe, is welcoming Steffen Wagner as its new CEO.
Wagner joins from Stada, where he was a member of the Global Executive Committee and responsible for European markets. A medical doctor by training, he has previously held senior roles at Biogen and within the Novartis Group, and worked as a consultant at McKinsey and Bain.
In addition, Wagner brings extensive international pharma experience that will be highly valuable in driving Advanz Pharma’s continued journey to be the partner of choice for commercializing specialty pharmaceuticals, specialty and hospital generics in Europe, the company said.
Wanger was appointed together with several other recent senior leadership hires as Advanz Pharma now enters into the next phase of its growth journey. These appointments include new CFO Andreas Stickler, who joined from Merck KGaA, and Susanna El-Armale, who joined as chief corporate development officer from Theramex.
“This is a hugely exciting time to be joining Advanz Pharma. It is a great platform on which we can build to achieve our vision to be a partner of choice in specialty pharmaceuticals in Europe,” Wagner said. “We will further expand the commercial footprint and accelerate growth via mergers and acquisitions, business development and licensing, and product launches. I am looking forward to working with my Advanz Pharma colleagues and helping to improve patients’ lives by providing the critical medicines they depend on.”